The microfluidic approach offered by this invention eliminates the problem of diffusion-based antibody-antigen binding interactions, and offers shorter reaction times. Furthermore, this invention uses small sample volumes that do not need prior purification.
[Detail]
This new technology addresses the fundamental issues arising in the emerging biotechnology of gene editing, off-target effects from prolonged treatment. Specifically, this invention improves the CRISP
[Detail]
| |< <- | [3121] [3122] [3123] [3124] [3125] [3126] [3127] [3128] [3129] [3130] [3131] |

